Skip to content
Lovastatin
Altoprev (lovastatin) is a small molecule pharmaceutical. Lovastatin was first approved as Mevacor on 1987-08-31. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA. The pharmaceutical is active against 3-hydroxy-3-methylglutaryl-Coenzyme A reductase. In addition, it is known to target nuclear receptor subfamily 1 group I member 2 and integrin alpha-L.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Altoprev (generic drugs available since 2001-12-17, discontinued: Mevacor)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lovastatin
Tradename
Company
Number
Date
Products
ALTOPREVCovis PharmaN-021316 RX2002-06-26
3 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
altoprevNew Drug Application2020-09-25
lovastatinANDA2023-06-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
coronary artery disease—D003324I25.1
hypercholesterolemiaHP_0003124D006937—
hyperlipoproteinemias—D006951—
hypertriglyceridemiaEFO_0004211D015228—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AA: Hmg coa reductase inhibitors, plain lipid modifying drugs
— C10AA02: Lovastatin
— C10B: Lipid modifying agents, combinations
— C10BA: Combinations of various lipid modifying agents
— C10BA01: Lovastatin and nicotinic acid
HCPCS
No data
Clinical
Clinical Trials
60 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InflammationD0072491—112115
Dry eye syndromesD015352H04.121234212
Allergic conjunctivitisD003233EFO_0007141H10.441113—6
Keratoconjunctivitis siccaD007638EFO_1000906—221—5
ConjunctivitisD003231H10——12—3
Ocular hypertensionD009798EFO_1001069H40.0———112
Meibomian gland dysfunctionD000080343H02.88———112
PseudophakiaD019591———112
Corneal edemaD015715EFO_1000879H18.20———2—2
Fuchs' endothelial dystrophyD005642EFO_0003946H18.51———2—2
Show 7 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PainD010146EFO_0003843R52——5——5
CataractD002386EFO_0001059H26.9——4——4
BlepharitisD001762EFO_0009536H01.0—12——3
KeratitisD007634H16——2——2
Bacterial conjunctivitisD003234EFO_1000829H10.0——1——1
KeratoconjunctivitisD007637H16.2——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypersensitivityD006967EFO_0003785T78.401————1
KeratoconusD007640EFO_0004223H18.61————1
Healthy volunteers/patients—1————1
Eye painD058447HP_0200026H57.11————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sjogren's syndromeD012859EFO_0000699M35.0————11
Macular edemaD008269————11
Retinal vein occlusionD012170EFO_1001157H34.81————11
Macular degenerationD008268EFO_0001365H35.30————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLOVASTATIN
INNlovastatin
Description
Lovastatin is a fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom). It has a role as an Aspergillus metabolite, a prodrug, an anticholesteremic drug and an antineoplastic agent. It is a polyketide, a statin (naturally occurring), a member of hexahydronaphthalenes, a delta-lactone and a fatty acid ester. It is functionally related to a (S)-2-methylbutyric acid and a mevastatin.
Classification
Small molecule
Drug classenzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
Identifiers
PDB7KC6
CAS-ID75330-75-5
RxCUI6472
ChEMBL IDCHEMBL503
ChEBI ID40303
PubChem CID53232
DrugBankDB00227
UNII ID9LHU78OQFD (ChemIDplus, GSRS)
Target
Agency Approved
HMGCR
HMGCR
Organism
Homo sapiens
Gene name
HMGCR
Gene synonyms
NCBI Gene ID
3156
Protein name
3-hydroxy-3-methylglutaryl-Coenzyme A reductase
Protein synonyms
3-hydroxy-3-methylglutaryl CoA reductase (NADPH), HMG-CoA reductase, hydroxymethylglutaryl-CoA reductase
Uniprot ID
Q8N190
Mouse ortholog
Hmgcr (15357)
3-hydroxy-3-methylglutaryl-coenzyme A reductase (Q5U4I2)
Alternate
NR1I2
NR1I2
ITGAL
ITGAL
Organism
Homo sapiens
Gene name
NR1I2
Gene synonyms
PXR
NCBI Gene ID
8856
Protein name
nuclear receptor subfamily 1 group I member 2
Protein synonyms
Orphan nuclear receptor PAR1, Orphan nuclear receptor PXR, Pregnane X receptor, Steroid and xenobiotic receptor, SXR
Uniprot ID
Q9UNW4
Mouse ortholog
Nr1i2 (18171)
nuclear receptor subfamily 1 group I member 2 (O54915)
Variants
Clinical Variant
Identifier
Target mutation
Effect
Evaluation
Status
VCV000037346SLCO1B1, 521T>C, Val174Aladrug response2022-02-151A
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 15,836 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,814 adverse events reported
View more details